Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

GLOW: Assistenza di Affermazione di Genere e Salute Mentale: Uno Studio Longitudinale sulla Qualità della Vita, Vita Lavorativa e Risultati Sanitari (GLOW)

25 settembre 2026 aggiornato da: Region Skane

GLOW: Assistenza Affermativa di Genere e Salute Mentale: Uno Studio Longitudinale sulla Qualità della Vita, Vita Lavorativa e Risultati Sanitari

Gender-Affirming Care and Mental Health (GLOW) investigates the psychological, medical, and social factors that influence the outcomes of gender-affirming care, as well as its impact on mental health, work capacity, and quality of life. Gender dysphoria is defined as the incongruence of a person's experienced gender and sex assigned at birth. In Sweden, the prevalence of gender dysphoria has increased significantly in recent decades. Still there is no consensus on the long-term outcomes ofgender-affirming care. 1. What are the baseline characteristics in individuals seeking gender-affirming care and do any of these predict outcomes of gender-affirmative care?2. Do individuals with gender dysphoria experience improved or reduced quality of life, gender congruence, or functional capacity after gender-affirming care?3. Does gender-affirming care reduce or increase psychiatric symptoms and self-concept clarity?4. What are the effects of gender-affirming care on mortality, work capacity, and healthcare resource utilization as compared to an age and gender matched control group?Data and MethodGLOW targets patients at the Gender Dysphoria Clinic, Region Skåne and Linköping a National Highly Specialized Care unit (NHV). Mixed methods will be used to analyze data from national registries and self-reported assessments.The NHV status ensures standardized high-quality data collection and clinical follow-up, making this project a unique opportunity to evaluate the care given to individuals with gender dysphoria.Societal Relevance and Utility The growing demand for gender-affirming care underscores the need for research to identify the most effective interventions. The results may also help reduce stigma and improve social integration for individuals with genderdysphoria.GLOW is a longitudinal mixed-methods study based at the NHV Gender Dysphoria Clinic in Region Skåne. It includes registry-based, qualitative interviews and repeated self-report measures up to 5 years after baseline assessment. Quantitative analyses will include regression models and Bayesian methods.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Descrizione dettagliata

The GLOW study is a longitudinal investigation designed to evaluate the effects of gender-affirming care on the well-being of individuals diagnosed with gender dysphoria in Sweden. Grounded in an interdisciplinary framework, the study adopts a mixed-methods approach to integrate quantitative registry data and longitudinal self-assessments with in-depth qualitative interviews. This design allows for anunderstanding of the medical, psychological, and social dimensions of gender-affirming care beyond the limitations of cross-sectional studies.The project is embedded in Linköping and Region Skåne's National Highly Specialized Care (NHV) unit, ensuring standardized data collection and uniform clinical procedures across participants. Thus, the study benefits from a stable clinical infrastructure and reliable access to a diverse cohort undergoing gender-affirming assessment and treatment. In addition, national health and population registries provide extensive data for long-term follow-up, including health service utilization, prescription records, socio-economic indicators, and mortality data.GLOW is commited to a collaborative research practice. The project actively involves key stakeholders-healthcare professionals, policymakers, and patient advocacy groups such as Transammans and RFSL. Their input ensures that the study remains aligned with real-world clinical needs and community priorities, enhancing its relevance.The study is conceptually anchored in the Biopsychosocial Model and draws on Minority Stress Theory, Self-Concept Clarity Theory, and Gender Affirmation Theory. These frameworks support the exploration of how social stressors, identity development, and access to affirming care interact to shape mental health trajectories. This theoretical integration provides a solid foundation for interpreting variability in treatment response and quality-of-life outcomes.Statistical modeling will be employed to complement traditional analyses, offering probabilistic interpretations and greater flexibility in handling complex longitudinal data structures. Qualitative interviews will be analyzed using thematic methods, with findings triangulated against quantitative trends to increase the validity and depth of insights.While many existing studies on gender-affirming care focus on short-term or medical outcomes, GLOW takes a broader and longer-term perspective. It includes economic implications, healthcare resource use, work life outcomes, and subjective experiences of identity and social integration. This holistic approach will generate knowledge applicable to clinical care, policy formulation, and public health planning.Finally, the project emphasizes sustainability. Infrastructure and data collection protocols have been designed to support extended follow-up. In doing so, GLOW aims to contribute not only to scientific literature but also to the development of evidence-based guidelines and inclusive healthcare systems.

Research Questions Taken together, understanding the trajectories of gender dysphoria is crucial. Such research can help determine which individuals benefit most from gender-affirming care and who might dropout during the process or experience dissatisfaction post-transition. Adapting current services to meet individual needs is essential. The current project will employ both quantitative and qualitative methods integrated into the clinical practice at the Gender Dysphoria Clinic, Region Skåne a National Highly Specialized Care unit (NHV), along with information from relevant databases and registries to achieve this goal.

  1. What are the baseline characteristics in individuals seeking gender-affirming care and do any of these predict outcomes of gender-affirmative care?
  2. Do individuals with gender dysphoria experience improved or reduced quality of life, gender congruence, or functional capacity after gender-affirming care?
  3. Does gender-affirming care reduce or increase psychiatric symptoms and self-concept clarity?
  4. What are the effects of gender-affirming care on mortality, work capacity, and healthcare resource utilization as compared to an age and gender-controlled comparison group?

Tipo di studio

Osservativo

Iscrizione (Stimato)

500

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Malmö
      • Malmö, Malmö, Svezia
        • Reclutamento
        • The Gender Dysphoria Clinic at Skåne University Hospital, Malmö, Sweden
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

N/A

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Participant recruitment will take place at the NHV Gender Dysphoria Clinic in Malmö, Region Skåne, which is one of Sweden's national centers for the diagnosis and treatment of gender dysphoria.

Descrizione

Inclusion Criteria:

  • All adults (18+) referred to the NHV clinic for gender dysphoria assessment in Region Skåne.

Exclusion Criteria:

  • Inability to read/write Swedish
  • Protected identity status

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Disforia di genere

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Quality of Life
Lasso di tempo: Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months

World Health Organization Disability Assessment Schedule (WHODAS 2.0) to evaluate general health status and functioning.

Score is converted to a 0-100 scale, where a higher score indicates greater disability or limitation in functioning.

Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Generalized Anxiety Disorder Scale (GAD-7)
Lasso di tempo: At the beginning of the clinical assessment, end of the assessment (usually 1 year after start), at 24 months and 60 months.

Generalized Anxiety Disorder Scale (GAD-7). The range of GAD 7 is 0 to 21. Higher scores indicate greater severity of anxiety symptoms.

At the beginning of the clinical assessment, end of the assessment (usually 1 year after start), at 24 months and 60 months.
Substance use
Lasso di tempo: Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months.

AUDIT produces a score from 0 to 40, with higher scores indicating a greater likelihood of hazardous, harmful, or dependent drinking.

Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months.
Substance use
Lasso di tempo: Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months.

Measured using the Drug Use Disorders Identification Test (DUDIT). DUDIT produces a score from 0 to 44, with higher scores indicating more severe drug-related problems or potential dependence.

Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months.
Self-Concept Clarity and Identity Functioning
Lasso di tempo: Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months.

Measured via the Self-Concept and Identity Measure (SCIM) and Level of Personality Functioning Scale - Brief Form 2.0 (LPFS 2).

SCIM has a total score range from 36 to 180, with higher scores indicating greater identity disturbance, LPFS has a range of 12 to 48, where a higher score indicates greater dysfunction.

Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months.
Change in Mental Health Symptoms
Lasso di tempo: Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months

Measured using the Generalized Anxiety Disorder Scale (GAD-7). The range of GAD 7 is 0 to 21. Higher scores indicate greater severity of anxiety symptoms.

Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months
Change in Mental Health Symptoms
Lasso di tempo: Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months

Questions regarding number of suicidal behavior.

Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months
Gender Congruence and Life Satisfaction
Lasso di tempo: Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months

Measured using the Gender Congruence Life Satisfaction Scale (GCLS). Range is 0 to 50. A higher score indicates a more positive outcome (higher gender congruence, better gender-related mental well-being, and better general life satisfaction).

Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months
Mortality
Lasso di tempo: 60 months

Source: Cause of Death Register (CDR)

60 months
Work Capacity and Socioeconomic Participation
Lasso di tempo: Baseline and 60 months

Derived from the Longitudinal Integration Database for Health Insurance and Labour Market Studies (LISA), including employment status and income.

Baseline and 60 months
Healthcare Utilization
Lasso di tempo: Baseline and 60 months

Source: National Patient Register (NPR) Metrics: Number of hospital visits.

Baseline and 60 months
Healthcare Utilization
Lasso di tempo: Baseline and 60 months

Source: Prescribed Drug Register Metrics: Use of medications (number of doses)

Baseline and 60 months
Healthcare Utilization
Lasso di tempo: Baseline and 60 months.

Source: National Patient Register (NPR) Metrics: Psychiatric diagnoses.

Baseline and 60 months.
EQ5d
Lasso di tempo: Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months

The EuroQol 5-Dimension (EQ-5D) assesses health-related quality of life. In the EQ-5D, each response generates a single-digit code between 1 and 5, where 1 = no problems and 5 = extreme problems. These single-digit codes can be combined to form a five-digit code corresponding to a specific health profile. Each dimension has five possible responses, meaning that together they can generate 3,125 different health profiles.

Baseline, after assessment completion (an average of 1 year), 24 months, and 60 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 dicembre 2025

Completamento primario (Stimato)

1 dicembre 2030

Completamento dello studio (Stimato)

1 dicembre 2030

Date di iscrizione allo studio

Primo inviato

13 marzo 2026

Primo inviato che soddisfa i criteri di controllo qualità

13 marzo 2026

Primo Inserito (Effettivo)

18 marzo 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

30 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

25 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2024-07577-02

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .